

**UW PACC** Psychiatry and Addictions Case Conference UW Medicine | Psychiatry and Behavioral Sciences

# **EXTENDED-RELEASE BUPRENORPHINE**

# JOSEPH MERRILL MD MPH PROFESSOR OF MEDICINE UNIVERSITY OF WASHINGTON







# **SPEAKER DISCLOSURES**

 $\checkmark$  No conflicts of interest



#### **Extended-Release Buprenorphine**

- Thanks to Jamie Darnton and his NWAETC talk!
- References:
  - Haight BR, et al. Lancet. 2019 Feb 23;393(10173):778-790.
  - Ardorn AC, et al. J Clin Psychopharmacol. May/Jun 2020;40(3):231-239.
  - Ling W, et al. J Addict Med. Nov/Dec 2019;13(6):442-449.
  - Lofwall MR et al. JAMA Intern Med. 2018 Jun 1;178(6):764-773.
  - Alyssa M, et al. J Subst Abuse Treat. 2021 Jul;126:108316.
  - Lintzeris N, et al. JAMA Netw Open. 2021 May 3;4(5):e219041.
  - Lee JD, et al. JAMA Netw Open. 2021 Sept 1;4(9):e2123032.
  - Mariani, et al. Am J Addict. 2020 Jul;29(4):345-348.



#### Case

- 49 year old with opioid use disorder on buprenorphine SL
  - Has remained engaged in treatment for 3 months
  - Struggled with buprenorphine adherence, intermittent use of fentanyl, and methamphetamine use
  - Most but not all his urine toxicology tests have had buprenorphine present – reported his medication was stolen
  - Due to this instability, he has continued to have weekly buprenorphine dispensing and he sometimes misses appointments and request refills the next day
- Could he benefit from extended-release buprenorphine?



# Background

- Buprenorphine is a partial opioid agonist with high receptor affinity that is effective for OUD treatment
- Limitations of SL buprenorphine/naloxone:
  - Treatment retention ~50% over 6-12 months
  - Requires daily medication adherence
  - Adherence interruptions are dangerous (e.g. jail)
  - Diversion concerns impede access, especially for polysubstance users
- Extended-release formulations may have advantages



#### **Extended-Release Buprenorphine Products**



Sublocade: FDA approved 2017



Brixadi: Not commercially available



Probuphine: Low uptake Sales discontinued in 2020



#### **Potential Populations**

- Adherence challenges (e.g. taste, sharing, using)
- Visit adherence challenges
- Difficulty safely storing buprenorphine
- Provider concerns about monitoring or diversion
- Leaving incarceration pilot trial just published
- Initiating in the ED trial ongoing



## Sublocade<sup>®</sup>

- Monthly SQ injection turns solid, RN can administer
- Trial started with at least 1 week of BUP-SL
- Two doses: 300mg (1.5ml) and 100mg (0.5ml)
- FDA label: 300mg Q month x 2, then 100mg Q month
- SQ injection to abdomen only, can be painful
  - Pre-medicate with lidocaine or ice
- Secure storage required IV use can cause thromboembolic events



# **Risk Evaluation and Mitigation Strategy (REMS)**

- FDA requirements to assure medication safety
- Restricts distribution to avoid IV misuse
- <u>Sublocade cannot be dispensed directly to a patient</u>
- Two options for providers to obtain Sublocade:
  - Through a certified pharmacy for a named patient
  - Have your organization become a certified distributor
- Certified distributors must assure that REMS requirements are followed (training, protocols)
- Other local pharmacy policies can complicate access



# **Evidence of Efficacy**




• M is the second s injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

> Barbara R Haight, Susan M Learned, Celine M Laffont, Paul J Fudala, Yue Zhao, Amanda S Garofalo, Mark K Greenwald, Vijay R Nadipelli, Walter Ling, Christian Heidbreder, for the RB-US-13-0001 Study Investigators\*

- 504 adults with moderate-severe OUD randomized to:
  - BUP-XR 300mg monthly
  - BUP-XR 300mg X 2 months, then 100mg monthly
  - Placebo injections
- Primary outcome: % weekly UDT/self-report negative for opioids
- Everyone received individual drug counseling



#### Results





#### Safety

	BUP-XR 300/300 mg plus individual drug counselling (n=201) (n=201)	BUP-XR 300/100 mg plus individual drug counselling (n=203) (n=203)	Placebo plus individual drug counselling (n=100)
Any treatment-emergent adverse event	134 (67%)	155 (76%)	56 (56%)
Any serious treatment-emergent adverse event	7 (3%)	4 (2%)	5 (5%)
Any severe treatment-emergent adverse event	13 (6%)	15 (7%)	4 (4%)
Any treatment-emergent adverse event leading to discontinuation	10 (5%)	7 (3%)	2 (2%)
Any treatment-emergent adverse event leading to death	1(<1%)	0	0
Treatment-emergent adverse events, by preferred term*			
Headache	17 (8%)	19 (9%)	6 (6%)
Constipation	16 (8%)	19 (9%)	0
Nausea	16 (8%)	18 (9%)	5 (5%)
Injection-site pruritus	19 (9%)	13 (6%)	4 (4%)
Vomiting	11 (5%)	19 (9%)	4 (4%)
Insomnia	17 (8%)	13 (6%)	11 (11%)
Upper respiratory tract infection	12 (6%)	15 (7%)	1(1%)
Injection-site pain	12 (6%)	10 (5%)	3 (3%)
Nasopharyngitis	10 (5%)	11 (5%)	1(1%)
Fatigue	12 (6%)	8 (4%)	3 (3%)
Anxiety	8 (4%)	10 (5%)	5 (5%)
Drug withdrawal syndrome	7 (3%)	9 (4%)	6 (6%)
Blood creatine phosphokinase increase	5 (2%)	11 (5%)	1(1%)
Diarrhoea	5 (2%)	5 (2%)	5 (5%)

\*Reported in at least 5% of participants in any treatment group during the double-blind phase.

Table 4: Treatment-emergent adverse events (safety analysis set)




# **Trial Summary**

- XR-BUP in two dosing schemes showed improved retention and abstinence vs placebo
- Not powered to detect difference between dosing regimens
- Safety similar to BUP-SL except for injection site reactions
- All aspects of the study were influenced by Indivior
- The comparison is to PLACEBO, not BUP-SL



#### **Additional Findings**





15

#### **Brixadi<sup>®</sup> – Another BUP-XR Product**

- Not currently FDA approved due to licensing issues
  - December 2021 FDA Response Letter cited only manufacturing issues
- Weekly and monthly doses tested
- Double dummy RTC showed Brixadi in 428 adults with OUD was non-inferior to BUP-SL for treatment retention and superior for opioid use
- Another RTC demonstrated improved patientcentered outcomes with weekly/monthly Brixadi vs BUP-SL dispensed at least weekly



#### **Observational Study of BUP-XR in Practice**

- 40 patients at MGH Bridge Clinic (78% unhoused)
- 27 retained on BUP-XR, 12 stopped (most commonly due to preference for BUP-SL), 1 LTFU
- 12 remained on 300mg BUP-XR monthly
- 22 used BUP-SL (4-24mg) after starting BUP-XR
- 12 started BUP-XR < 7days after starting BUP-SL
- Illicit opioid negative UDT 65%
- No precipitated withdrawal or overdoses




## **Pilot Trial at Time of Release from Jail**

- Open-label randomized comparative effectiveness pilot trial (N=52) of BUP-XR vs BUP-SL at jail release
- Primary outcome was retention 8 weeks after release
- BUP-XR group had fewer jail medical visits
- Community treatment retention at 8 weeks was 69% for BUP-XR and 35% for BUP-SL
- Opioid negative urine tests were 55% for BUP-XR and 38% for BUP-SL



#### **Serum Levels and Dosing**

- Steady-state achieved in 2 months for 100mg group
- Steady-state achieved in 6 months for 300mg group





## **Dosing Considerations**

- For folks who continue to use extra-medical opioids or experience cravings after their second injection of 300mg, it is reasonable to consider staying at 300mg
- For folks who experience increased instability or craving after reduction to 100mg, it is reasonable to consider increasing back to 300mg
- Supplemental SL dosing may be necessary for some patients who continue to experience craving or withdrawal after their first few injections



# Troubleshooting

- In general, if a patient is late for an injection, they can be administered the dose within 2 weeks without compromising treatment or risking precipitated withdrawal
- Patients may test positive for buprenorphine months after last injection



#### Summary

- Injectable buprenorphine-XR may be a good option for patients with concerns around diversion, regular adherence, or regular attendance
- Favorable safety profile with adverse events similar to BUP-SL plus generally mild injection site reactions
- Few direct comparisons to buprenorphine-SL for the available formulation
- Some patients may need supplemental SL dosing
- Some may need to remain at 300mg monthly



#### Discussion

- Is anyone using Sublocade?
- What are the barriers?
  - Outpatient
  - Inpatient
- Can we start BUP-XR without BUP-SL first?



# Thank You!

